- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04185402
Azithromycin Reduction to Reach Elimination of Trachoma (ARRET)
January 17, 2024 updated by: University of California, San Francisco
The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maradi, Niger.
The investigators will randomize communities with up to 20% Trachomatous Inflammation - Follicular (TF) prevalence following at least 5 years of mass azithromycin distribution to discontinuation or continuation of 3 additional years of annual mass azithromycin distribution.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
100000
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Catherine Oldenburg, ScD, MPH
- Phone Number: (415) 502-8843
- Email: catherine.oldenburg@ucsf.edu
Study Contact Backup
- Name: Aimée Kimfuema, MPH
- Phone Number: 4155022662
- Email: mponda.kimfuema@ucsf.edu
Study Locations
-
-
-
Niamey, Niger
- Recruiting
- Programme National de Santé Oculaire (PNSO)
-
Contact:
- Abdou Amza, MD
- Phone Number: +227 96967009
- Email: dr.amzaabdou@gmail.com
-
Principal Investigator:
- Abdou Amza, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Provision of appropriate informed consent
- Stated willingness to comply with all study procedures
- Live in one of the 80 communities with up to 20% prevalence of TF selected for the trial
Exclusion Criteria:
- Does not consent to participation
- Unwilling to comply with all study procedures
- Does not live in one of the 80 communities with up to 20% prevalence of TF selected for the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Azithromycin Continuation
In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits.
Oral azithromycin, 20 mg/kg for children and 1 g for adults, will be offered to all households identified on the preceding census in the communities randomized to continuing treatment.
Study drug will be distributed by health extension workers and organized by PNSO.
Individuals with a known macrolide allergy will be offered a two-week course of daily ophthalmic tetracycline ointment (two tubes).
|
In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits.
In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
|
No Intervention: Azithromycin Discontinuation
In study communities randomized to the Azithromycin Discontinuation arm, individuals will receive no treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ocular chlamydia measured in a population-based sample of 0-9 year-old children
Time Frame: 36 months
|
Assessed by PCR
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Infectious load of chlamydia among 0-9 year-old children infected with ocular chlamydia
Time Frame: 36 months
|
Assessed by PCR
|
36 months
|
Conjunctival inflammation
Time Frame: 36 months
|
Assessed from conjunctival photography.
Clinical photographs of the conjunctiva will be assessed by masked graders according to the grading scale described by the WHO Simplified Grading System.
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Elodie Lebas, RN, University of California, San Francisco
- Principal Investigator: Tom Lietman, MD, University of California, San Francisco
- Principal Investigator: Catherine Oldenburg, ScD, MPH, University of California, San Francisco
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 29, 2021
Primary Completion (Estimated)
October 31, 2026
Study Completion (Estimated)
October 31, 2026
Study Registration Dates
First Submitted
December 2, 2019
First Submitted That Met QC Criteria
December 2, 2019
First Posted (Actual)
December 4, 2019
Study Record Updates
Last Update Posted (Estimated)
January 19, 2024
Last Update Submitted That Met QC Criteria
January 17, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Eye Diseases
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Conjunctivitis
- Conjunctival Diseases
- Corneal Diseases
- Chlamydiaceae Infections
- Eye Infections, Bacterial
- Eye Infections
- Chlamydia Infections
- Conjunctivitis, Bacterial
- Trachoma
- Anti-Infective Agents
- Anti-Bacterial Agents
- Azithromycin
Other Study ID Numbers
- 19-28923
- 5UG1EY030833 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trachoma
-
University of California, San FranciscoNational Eye Institute (NEI); Institut National de Recherche Biomédicale. Kinshasa...Not yet recruitingTrachomaCongo, The Democratic Republic of the
-
Emory UniversityThe Carter CenterSuspended
-
University of California, San FranciscoCompleted
-
Johns Hopkins UniversityBill and Melinda Gates FoundationCompleted
-
University of California, San FranciscoNational Eye Institute (NEI); Emory University; The Carter Center; Amhara Public...Recruiting
-
London School of Hygiene and Tropical MedicineUniversity College London Hospitals; World Health Organization; RTI International and other collaboratorsTerminated
-
London School of Hygiene and Tropical MedicineFederal Minstry of Health of Ethiopia; Oromia Regional Health Bureau, Ethiopia and other collaboratorsCompletedTrachomaUnited Kingdom, Ethiopia
-
Johns Hopkins UniversityNational Eye Institute (NEI)Completed
-
Johns Hopkins UniversityWellcome TrustCompletedTrachomaUnited States
-
Laboratoires TheaCompleted
Clinical Trials on Azithromycin
-
PfizerCompletedTonsillitis | PharyngitisBelgium, India, Germany, United States, France, United Kingdom, Netherlands, Finland, Italy, Norway
-
Washington University School of MedicineCompletedRespiratory Syncytial Virus, BronchiolitisUnited States
-
Sheba Medical CenterUnknown
-
PfizerCompletedBacterial Infections
-
Thomas Jefferson UniversityChristiana Care Health ServicesCompletedPreterm Premature Rupture of MembraneUnited States
-
GlaxoSmithKlineCompletedAutoimmune DiseasesUnited Kingdom
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedPostpartum Sepsis | Postpartum Endometritis | Postpartum FeverCameroon
-
Emory UniversityThe Carter CenterSuspended
-
University of Alabama at BirminghamCompletedRespiratory Syncytial VirusUnited States